Physician profile
Sue Lee
NPI 1720086317
$5,761.08
in general payments reported to CMS, 2019-2025
31 companies · $37.14 in 2025
The $37.14 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $130 · 2021: $472 · 2022: $1,397 · 2023: $1,025 · 2024: $1,904 · 2025: $37.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,295.98 | 2024 | Omvoh |
| Abbvie INC. | $802.66 | 2019-2024 | |
| Amgen INC. | $459.31 | 2019-2023 | Repatha, Amjevita, Avsola |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.48 | 2019-2025 | Trulance, Xifaxan |
| Pfizer INC. | $400.42 | 2019-2024 | |
| Janssen Biotech, INC. | $350.31 | 2019-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $305.06 | 2021-2024 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $272.00 | 2022-2024 | Dupixent |
| Celgene Corporation | $210.13 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $202.26 | 2019-2024 | Sucraid, Sucraid |
| Medtronic, INC. | $156.15 | 2022-2023 | Gi Genius |
| E.R. Squibb & Sons, L.L.C. | $116.87 | 2019 | |
| Braintree Laboratories, INC. | $95.72 | 2020-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $79.93 | 2019-2020 | |
| Ardelyx, INC. | $77.56 | 2023-2024 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.56 | 2022-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $51.92 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $47.40 | 2022-2023 | |
| Organon LLC | $41.65 | 2023 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $40.31 | 2022-2023 | Ocaliva |
| Genzyme Corporation | $35.18 | 2022-2023 | |
| Baxter Healthcare | $33.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.86 | 2022 | |
| Amag Pharmaceuticals, INC. | $24.19 | 2021-2022 | |
| Shionogi INC | $23.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $23.19 | 2019 | |
| Evoke Pharma, INC. | $21.25 | 2022 | |
| Mdd US Operations, LLC | $20.49 | 2025 | Xadago |
| Gilead Sciences, INC. | $19.69 | 2019 | |
| Celltrion USA INC. | $15.99 | 2024 | Zymfentra |
| Shield Therapeutics INC | $14.61 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.